Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer

JHOP - October 2022 Vol 12, No 5 - FDA Oncology Update
NEW DRUGS

On September 28, 2022, the FDA approved bevacizumab-adcd (Vegzelma; Celltrion), a VEGF inhibitor and a biosimilar to bevacizumab (Avastin), for the treatment of metastatic colorectal cancer; recurrent or metastatic nonsquamous non–small-cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal-cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer. Bevacizumab-adcd is not indicated for the adjuvant treatment of colon cancer.

Bevacizumab-adcd is the fourth biosimilar to bevacizumab to be approved by the FDA. The approval was based on the totality of evidence showing no clinically meaningful differences in efficacy, safety, or pharmacokinetics between bevacizumab-adcd and the reference drug, including the results of a double-blind, randomized phase 3 clinical trial of 689 patients with metastatic or recurrent nonsquamous NSCLC.

In that study, the patients received 15 mg/kg of bevacizumab-adcd intravenously every 3 weeks for up to 6 cycles in the induction phase, followed by every 3 weeks until disease progression in the maintenance phase. The main end point was objective response at 21 weeks. The results showed that bevacizumab-adcd was highly similar to its reference drug in efficacy, safety, and pharmacokinetics.

The most common (>10%) adverse events with bevacizumab-adcd are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, and exfoliative dermatitis.

Related Items
Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Akeega, First and Only Dual-Action Tablet for Metastatic Prostate Cancer With BRCA Mutation
Online First published on September 8, 2023 in FDA Oncology Update
FDA Granted Accelerated Approval to Elrexfio, a Bispecific BCMA-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Online First published on September 8, 2023 in FDA Oncology Update
Hepzato Kit FDA Approved as a Liver-Directed Treatment for Uveal Melanoma With Hepatic Metastases
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Online First published on September 8, 2023 in FDA Oncology Update
FDA Accelerated the Approval of Columvi for Selected Relapsed or Refractory Large B-Cell Lymphomas
JHOP - August 2023 Vol 13, No 4 published on August 17, 2023 in FDA Oncology Update
Lonsurf Received a New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer
JHOP - August 2023 Vol 13, No 4 published on August 7, 2023 in FDA Oncology Update
Jemperli Plus Chemotherapy Now FDA Approved for Front-Line Treatment of dMMR or MSI-H Endometrial Cancer
JHOP - August 2023 Vol 13, No 4 published on August 4, 2023 in FDA Oncology Update
Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML
JHOP - August 2023 Vol 13, No 4 published on July 28, 2023 in FDA Oncology Update
Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation
JHOP - August 2023 Vol 13, No 4 published on June 30, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.